-
公开(公告)号：US08603483B2
公开(公告)日：2013-12-10
申请号：US11290249
申请日：2005-11-30
Applicant: Qiming Chen , Mohit Trikha , Robert J. Lutz , Rita M. Steeves , Godfrey Amphlett
Inventor： Qiming Chen , Mohit Trikha , Robert J. Lutz , Rita M. Steeves , Godfrey Amphlett
CPC classification number: A61K47/48569 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2839 , C07K2317/21 , C07K2317/73
Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
Abstract translation: 本发明涉及抗整联蛋白特异性抗体与细胞毒性化合物的缀合物，用于癌症治疗或由细胞增殖，细胞迁移或炎症介导的其它疾病的这种缀合物的合成，选择和使用以及哪些病理学涉及血管生成或新生血管形成 的新组织。 此外，本发明涉及这些疾病的组合治疗，其中治疗包括使用所述缀合物与一种或多种其它治疗方式的组合，包括但不限于化疗，手术或放射治疗。 优选的缀合物含有通过二硫键与抗体连接的美登木素生物碱化合物，优选的化学治疗剂是多柔比星，紫杉烷，喜树碱，鬼臼毒素，核苷类似物或嘧啶类似物。
-
公开(公告)号：US07833786B2
公开(公告)日：2010-11-16
申请号：US11927925
申请日：2007-10-30
Applicant: Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
Inventor： Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
IPC: C12N5/12
CPC classification number: C07K16/248 , A01K67/0271 , A01K2267/0331 , A61K39/3955 , A61K2039/505 , C07K16/4241 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及至少一种衍生自鼠CLB-8抗体的新型嵌合，人源化或CDR移植的抗IL-6抗体，包括编码至少一种这样的抗IL-6抗体的分离的核酸，载体， 宿主细胞，转基因动物或植物，以及其制备和使用方法，包括治疗组合物，方法和装置。
-
公开(公告)号：US20080312172A1
公开(公告)日：2008-12-18
申请号：US11927925
申请日：2007-10-30
Applicant: Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
Inventor： Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
CPC classification number: C07K16/248 , A01K67/0271 , A01K2267/0331 , A61K39/3955 , A61K2039/505 , C07K16/4241 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及至少一种衍生自鼠CLB-8抗体的新型嵌合，人源化或CDR移植的抗IL-6抗体，包括编码至少一种这样的抗IL-6抗体的分离的核酸，载体， 宿主细胞，转基因动物或植物，以及其制备和使用方法，包括治疗组合物，方法和装置。
-
公开(公告)号：US20060127407A1
公开(公告)日：2006-06-15
申请号：US11290249
申请日：2005-11-30
Applicant: Qiming Chen , Mohit Trikha , Robert Lutz , Rita Steeves , Godfrey Amphlett
Inventor： Qiming Chen , Mohit Trikha , Robert Lutz , Rita Steeves , Godfrey Amphlett
IPC: A61K39/395 , C07K16/46
CPC classification number: A61K47/48569 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K16/2839 , C07K2317/21 , C07K2317/73
Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
-
公开(公告)号：US06218514B1
公开(公告)日：2001-04-17
申请号：US09343062
申请日：1999-06-29
Applicant: Mohit Trikha , Kenneth V. Honn
Inventor： Mohit Trikha , Kenneth V. Honn
IPC: A61K39395
CPC classification number: C07K14/82 , C07K14/70546
Abstract: tr-&agr;IIb, a soluble, truncated integrin found to be exclusively expressed in tumor cells is provided. An additional truncated integrin, tr-&bgr;3, has also been found to be exclusively expressed in tumor cells. Diagnostic compositions including nucleic acid probes and antibodies and methods for detecting the presence of tr-&agr;IIb and tr-&bgr;3 to identify the presence of tumor cells in a sample are also provided.
Abstract translation: tr-αIIb是发现在肿瘤细胞中唯一表达的可溶性截短的整联蛋白。 还发现另外的截短整合素tr-β3仅在肿瘤细胞中表达。 还提供了包括核酸探针和抗体的诊断组合物和用于检测tr-αIIb和tr-β3的存在以鉴定样品中肿瘤细胞存在的方法。
-
Patent Agency Ranking
公开(公告)号：US20110218329A1
公开(公告)日：2011-09-08
申请号：US13105152
申请日：2011-05-11
Applicant: Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
Inventor： Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
IPC: C07K16/24
CPC classification number: C07K16/248 , A01K67/0271 , A01K2267/0331 , A61K39/3955 , A61K2039/505 , C07K16/4241 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及至少一种衍生自鼠CLB-8抗体的新型嵌合，人源化或CDR移植的抗IL-6抗体，包括编码至少一种这样的抗IL-6抗体的分离的核酸，载体， 宿主细胞，转基因动物或植物，以及其制备和使用方法，包括治疗组合物，方法和装置。
-
公开(公告)号：US07288390B2
公开(公告)日：2007-10-30
申请号：US09920267
申请日：2001-08-01
Applicant: George Heavner , Jill Giles-Komar , Linda Snyder , Mohit Trikha
Inventor： George Heavner , Jill Giles-Komar , Linda Snyder , Mohit Trikha
CPC classification number: G01N33/5008 , A01K2217/05 , A01K2267/01 , A61K2039/505 , C07K16/2839 , C07K2317/21 , C07K2317/565 , C07K2317/92 , G01N33/5029 , G01N33/68 , G01N2333/70546 , Y02A50/58
Abstract: The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及至少一种新的抗双重整联蛋白抗体，包括编码至少一种抗双重整联蛋白抗体，双重整联蛋白，载体，宿主细胞，转基因动物或植物的分离核酸及其制备和使用方法 ，包括治疗组合物，方法和装置。
-
公开(公告)号：US20070128203A1
公开(公告)日：2007-06-07
申请号：US11598411
申请日：2006-11-13
Applicant: Jill Giles-Komar , Linda Snyder , Mohit Trikha , Marian Nakada
Inventor： Jill Giles-Komar , Linda Snyder , Mohit Trikha , Marian Nakada
IPC: A61K39/395 , A61K38/18 , A61K31/56 , A61K31/7052 , A61K31/137
CPC classification number: C07K16/2839 , A01K2217/05 , A01K2267/01 , A61K2039/505 , C07K16/2848 , C07K16/4258 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/5008 , G01N33/5029 , G01N33/68 , G01N2333/70546 , Y02A50/58
Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
-
公开(公告)号：US20120096569A1
公开(公告)日：2012-04-19
申请号：US13332973
申请日：2011-12-21
Applicant: Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
Inventor： Jill Giles-Komar , David Knight , David Peritt , Mohit Trikha
IPC: A61K39/395 , C12P21/00 , A61K51/00 , C12N5/071 , C07K16/24 , A01K67/027 , A01H5/00 , A61P29/00 , A61P19/02 , A61P1/00 , A61P37/06 , A61P27/02 , A61P11/00 , A61P37/08 , A61P11/06 , A61P11/02 , A61P17/00 , A61P1/18 , A61P7/06 , A61P3/10 , A61P13/12 , A61P7/00 , A61P1/16 , A61P19/10 , A61P35/00 , A61P35/02 , A61P31/00 , A61P17/06 , A61P7/02 , A61P11/14 , A61P1/08 , A61P1/04 , A61P1/10 , C07K16/46
CPC classification number: C07K16/248 , A01K67/0271 , A01K2267/0331 , A61K39/3955 , A61K2039/505 , C07K16/4241 , C07K2317/24 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及至少一种衍生自鼠CLB-8抗体的新型嵌合，人源化或CDR移植的抗IL-6抗体，包括编码至少一种这样的抗IL-6抗体的分离的核酸，载体， 宿主细胞，转基因动物或植物，以及其制备和使用方法，包括治疗组合物，方法和装置。
-
公开(公告)号：US08071333B2
公开(公告)日：2011-12-06
申请号：US12426996
申请日：2009-04-21
Applicant: Jill Giles-Komar , Linda Snyder , Mohit Trikha , Marian T. Nakada
Inventor： Jill Giles-Komar , Linda Snyder , Mohit Trikha , Marian T. Nakada
CPC classification number: C07K16/2839 , A01K2217/05 , A01K2267/01 , A61K2039/505 , C07K16/2848 , C07K16/4258 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/5008 , G01N33/5029 , G01N33/68 , G01N2333/70546 , Y02A50/58
Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及至少一种新的抗α-V亚基抗体，包括编码至少一种抗-α-V亚基抗体，α-V亚基，载体，宿主细胞，转基因动物或植物的分离的核酸，以及 制备和使用它们的方法，包括治疗组合物，方法和装置。
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.04 seconds)
